Purchase this article with an account.
P. L. Ballalai, C. M. Erwenne, M. C. Martins, J. N. Barros; Combined Use of Subconjunctival Bevacizumab and Topical Mitomycin C in the Treatment of Conjunctival Squamous Cell Neoplasia. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5225.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of the combined use of subconjunctival bevacizumab (Avastin) and topical Mitomycin C (MMC) in the treatment of primary or recurrent conjunctival Squamous cell carcinoma (SCC).
Were included in this study patients with clinical diagnosis of conjunctival SCC attended at the Ocular Tumor section of the Federal University of Sao Paulo. The diagnosis was confirmed by impression cytology. The patients received a subconjunctival injection of bevacizumab, 25 mg/0,1 ml, under topical anesthesia. Fourteen days after the injection, the patients used topical MMC 0,02%, qid, for 14 days. A total or partial regression of the lesions was observed.Patients with partial regression were then submitted to excisional biopsy.
Six patients were included in this study. Total regression of the tumor was observed in one patient and a partial regression in 5 patients, after the subconjunctival injection and 1 cycle of MMC. A reduction of the vascularization was observed after the Avastin injection in all patients and there was no ocular or systemic side effects. Mild hyperemia was the only side effect observed with the use of topical MMC.
The use of subconjunctival bevacizumab contributed to a total or partial regression of the conjunctival lesion, in association with topical MMC.The reduced number of cycles reduces the risks of ocular complications regarding the use of topical MMC.
This PDF is available to Subscribers Only